Vivesto

0.273

SEK

-1.09 %

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

2 following

-1.09%

-6.03%

+0.55%

+14.5%

-0.18%

-28.66%

-89.61%

-94.76%

-98.49%

Vivesto is a research company. The company specializes in the research and development of drugs for serious diseases in oncology. The technology is based on the company's technical platform where research is based on nanotechnology. Today, operations are conducted mainly in the Nordic countries and North America. The company was founded in 1999 and has its headquarters in Uppsala.

Market cap

146.62M SEK

Turnover

165.42K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

20.2

2025

Annual report '24

8.5

2025

General meeting '24

8.5

2025

Interim report Q1'25

ShowingAll content types

Press release12/19/2024, 10:00 AM

Vivesto strengthens Cantrixil program with new preclinical results and patent application

Press release11/11/2024, 10:33 AM

Vivesto’s Paccal Vet receives Limited Market classification in EU

Regulatory press release11/7/2024, 9:54 AM

Vivesto signs Apealea option agreement with Zhida Pharmaceutical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release7/1/2024, 6:00 AM

Vivesto receives positive Cantrixil preclinical efficacy data

Regulatory press release5/23/2024, 8:48 AM

Report from Annual General Meeting in Vivesto AB

Regulatory press release4/23/2024, 6:00 AM

Notice of Annual General Meeting in Vivesto AB

Press release3/19/2024, 12:06 PM

Vivesto to hold live-streamed Paccal Vet R&D Update on March 26

Regulatory press release3/7/2024, 7:10 AM

Vivesto doses first patient in its clinical Paccal Vet trial

Press release1/30/2024, 7:00 AM

Vivesto's international patent application for XR-18 receives positive decision

Press release12/28/2023, 7:00 AM

Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment

Regulatory press release12/22/2023, 4:26 PM

Vivesto’s Paccal Vet granted FDA MUMS designation

Regulatory press release12/22/2023, 3:28 PM

Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea

Press release12/19/2023, 11:28 AM

Vivesto reports positive preclinical data supporting continued development of Cantrixil

Regulatory press release11/23/2023, 8:11 PM

Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto

Regulatory press release11/23/2023, 6:30 AM

Vivesto and Elevar sign agreement ending Apealea® partnership

Regulatory press release11/16/2023, 7:00 AM

Interim report for the period January 1, 2023 – September 30, 2023

Regulatory press release10/25/2023, 5:30 AM

Vivesto focuses its project portfolio and introduces cost-saving measures

Regulatory press release9/15/2023, 7:19 PM

Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023

Regulatory press release8/24/2023, 6:00 AM

Interim report for the period January 1, 2023 – June 30, 2023

Press release8/4/2023, 6:30 AM

Vivesto announces early termination of patient enrollment in the investigator-initiated Phase 1b Docetaxel micellar study

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.